Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMP7068 Monotherapy in Advanced Solid Tumors
NCT04768868Phase 1Unknown
- Sponsor
- IMPACT Therapeutics
- Start
- Feb 2021
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of potrasertib in solid tumor (advanced stage), sponsored by IMPACT Therapeutics. Primary endpoints: Incidence of treatment emergent adverse events (TEAEs), Severity of treatment emergent adverse events (TEAEs) and 2 more. Status: unknown.
02
Drugs
potrasertib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04768868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04768868.